Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies1000
Regeneron
Regeneron Pharmaceuticals invents life-transforming medicines for people with serious diseases..
Sector
Subsector
Location
total rounds
total raised
count Of Investments
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical develops therapeutics for rare and ultra-rare diseases.
Sector
Subsector
Location
total rounds
total raised
count Of Investments
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops and commercializes controlled release combination therapeutics to treat healthcare problems.
Sector
Subsector
Location
total rounds
total raised
Tricida
Tricida develops and commercializes veverimer, a drug for metabolic acidosis in chronic kidney disease patients.
Sector
Subsector
Keywords
Location
total rounds
total raised
M&A Details2
Transaction name
Acquired by
Novo Holdings
announced date
price
Financials
Funding Rounds5
Number of Funding Rounds
Money Raised
Their latest funding was raised on 04.01.2021. Their latest investor CBC Group. Their latest round Post-IPO Debt
CBC Group
CBC Group is Asia's largest healthcare-dedicated asset management firm.
Sector
Subsector
Keywords
count Of Investments
Biomedical Advanced Research and Development Authority (BARDA)
BARDA develops and purchases vaccines, drugs, therapies, and diagnostic tools for emergencies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Co-Investors
Investors9
Number of lead investors
Number of investors
CBC Group
CBC Group is Asia's largest healthcare-dedicated asset management firm.
Sector
Subsector
Keywords
count Of Investments
IBT Management Corporation
IBT Management Corp invests in early- to mid-stage high tech companies to help them grow and gain a competitive advantage.
Sector
Subsector
Location
count Of Investments
count Of Exists
D. E. Shaw & Co.
D. E. Shaw & Co. is an investment firm specializing in equities, futures, and options trading.
Sector
Subsector
Location
total rounds
count Of Investments
count Of Exists
Acquisitions1
Transcept Pharmaceuticals acquired by Paratek Pharmaceuticals
acquirer
date
type
Transcept Pharmaceuticals
Transcept Pharmaceuticals enhances drug effectiveness through its proprietary delivery system.
Sector
Subsector
Keywords
Location
total rounds
total raised
People
Founders1
Walter Gilbert
Wally Gilbert is a leading molecular biologist, formerly a member of the Harvard faculty, and a founder of Biogen, serving as its Chairman and CEO from 1981 until 1985. After returning to Harvard University, he later became the Carl M. Loeb University Professor. He was an advisor to BVI at its inception and became a partner in 2003. In 1975, Wally developed a method of rapid DNA sequencing for which he received the Nobel Prize in Chemistry in 1980. He is a co-founder and Vice-Chairman of Myriad Genetics Inc. (NASDAQ: MYGN) and a co-founder and Chairman of Paratek Pharmaceuticals Inc. He was a co-founder and Director of Memory Pharmaceuticals Inc. (acquired by Roche). He also served as a Director of Transkaryotic Therapies (now Shire Human Genetic Therapies). While a member of the BioVentures Investors Fund I Board of Advisors, he co-founded Pintex Pharmaceuticals Inc., a Fund I portfolio company, and served as Chairman of the Board of Directors. As a BioVentures Investors Managing Director he served on the Board of Directors of Hospital Care Online, Pintex, ActivBiotics, Verax, Cylene, and Hydra Biosciences (obs). Wally earned an A.B. in Chemistry and Physics from Harvard College, an M.A. in Physics from Harvard University, and a Doctor of Philosophy in Mathematics from Cambridge University. He has several honorary doctorates
current job
count Of Investments
Walter Gilbert
Employee Profiles49
Bill Haskel
Chief legal officer, general counsel and corporate secretary
Jackie Barnard
Associate director, field reimbursement
Randy Brenner
Chief development and regulatory office
Karen Mcgrath
Senior vice president human resources
Jennifer Creaven
Senior manager, quality operations, regulatory and qa
Activity
Recent News7
The graph reveals the ratio (%) of positive news articles in a chosen time range